Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP

Key Points

• Swedbank AB opened a new position in Rapport Therapeutics during the fourth quarter, buying 113,200 shares worth about $3.43 million.
• Several other institutional investors also boosted or initiated stakes, including Baker Bros., Capital International Investors, and UBS AM, highlighting growing institutional interest in the stock.
• Analyst sentiment is mixed but generally positive: the stock carries a Moderate Buy consensus with a $58.83 target, while recent quarterly results beat estimates on both earnings and revenue.

Swedbank AB bought a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 113,200 shares of the company's stock, valued at approximately $3,434,000. Swedbank AB owned 0.24% of Rapport Therapeutics at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in RAPP. Baker BROS. Advisors LP lifted its position in Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock valued at $45,949,000 after purchasing an additional 997,000 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $28,215,000. Polar Capital Holdings Plc acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $27,887,000. Capital International Investors raised its position in shares of Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company's stock valued at $101,055,000 after acquiring an additional 800,000 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Rapport Therapeutics by 265.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company's stock valued at $26,500,000 after acquiring an additional 648,378 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on RAPP shares. Wall Street Zen upgraded shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Tuesday, April 21st. TD Cowen reiterated a "buy" rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Wells Fargo & Company increased their price target on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. Finally, Raymond James Financial started coverage on shares of Rapport Therapeutics in a research report on Friday, April 10th. They issued a "strong-buy" rating and a $66.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rapport Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $58.83.

Insider Activity

In other news, insider Krishnaswamy Yeleswaram sold 20,225 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the completion of the transaction, the insider owned 246,426 shares in the company, valued at $9,854,575.74. This represents a 7.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $40.32, for a total transaction of $17,176,521.60. Following the completion of the transaction, the insider owned 6,709,228 shares of the company's stock, valued at $270,516,072.96. This trade represents a 5.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 878,600 shares of company stock worth $35,223,398 over the last quarter. 13.57% of the stock is currently owned by company insiders.

Rapport Therapeutics Stock Down 0.5%

Rapport Therapeutics stock opened at $39.51 on Thursday. The stock has a market capitalization of $1.89 billion, a PE ratio of -15.20 and a beta of 0.82. Rapport Therapeutics, Inc. has a twelve month low of $7.73 and a twelve month high of $42.27. The company has a 50 day moving average of $34.36 and a 200-day moving average of $30.42.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.14. The company had revenue of $20.00 million during the quarter, compared to analyst estimates of $7.50 million. Equities analysts anticipate that Rapport Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.